Chi KN et al. Study evaluating metastatic castrate resistant prostate cancer (mCRPC) treatment using 177Lu-PNT2002 PSMA therapy after second-line hormonal treatment (SPLASH). ASCO 2021;Abstract TPS5087.
Delanoy N et al. Pain progression at initiation of cabazitaxel in metastatic castration resistant prostate cancer (mCRPC): A post hoc analysis of the PROSELICA study. Cancers (Basel) 2021;13(6):1284. Abstract
Fizazi K et al. Health-related quality of life (HRQoL), pain and safety outcomes in the phase 3 VISION study of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer. ESMO 2021;Abstract 576MO.
Jaeger E et al. ctDNA pathogenic variants (PVs) in homologous recombination repair (HRR) genes in patients with metastatic CRPC. ASCO Genitourinary Cancers Symposium 2021;Abstract 138.
Ledet EM et al. Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer. Prostate 2021;81(7):433-9. Abstract
Lin E et al. Identification of somatic gene signatures in circulating cell-free DNA associated with disease progression in metastatic prostate cancer by a novel machine learning platform. Oncologist 2021;26(9):751-60. Abstract
Marima R et al. Prostate cancer racial, socioeconomic, geographic disparities: Targeting the genomic landscape and splicing events in search for diagnostic, prognostic and therapeutic targets. Am J Cancer Res 2021;11(4):1012-30. Abstract
Sartor AO et al. A multicenter, randomized, controlled phase II study: Efficacy and safety of PSMA-targeted radioligand therapy I-131-1095 (1095) plus enzalutamide (enza) in 18F-DCFPyL PSMA scan avid, metastatic castration-resistant prostate cancer (mCRPC) patients post-abiraterone (abi) progression (ARROW). ASCO Genitourinary Cancers Symposium 2021;Abstract TPS187.
Sartor AO. PSMA-targeted radiotherapy in metastatic castration-resistant prostate cancer. Clin Adv Hematol Oncol 2021;19(8):494-6. Abstract
Sartor O et al. Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med 2021;385(12):1091-103. Abstract
Sokolova AO et al. Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations. Prostate 2021;81(16):1382-9. Abstract
Tagawa ST et al. Final results of phase I/II trial of fractionated dose 177Lu-PSMA-617 for metastatic castration-resistant prostate cancer (mCRPC). ESMO 2021;Abstract 600P.
Thiery-Vuillemin A et al. Post hoc health-related quality of life analysis according to response among patients with prostate cancer in the PROSELICA and FIRSTANA studies. Oncologist 2021;26(7):e1179-88. Abstract